AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9795022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration
Number of subjects: 0
Study 9795022 — intervention group
Group type: COMPARATOR
Intervention: Oral tablet
Number of subjects: 0
Study 9795022 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 0
Study 9795022 — intervention group
Group type: EXPERIMENTAL
Intervention: All routes
Number of subjects: 0
Study 7986489 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (25 to 500 mg daily, dose escalation phase)
Number of subjects: 12
Study 7986489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2929903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1 mg/kg
Number of subjects: 80
Study 2929903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5 mg/kg
Number of subjects: 80
Study 2929903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 2 mg/kg
Number of subjects: 80
Study 2929903 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 80
Study 30623490 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 284
Study 30623490 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 284
Study 27943397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopurine treatment with 6-MMP concentrations measured at T1 (1 week after treatment initiation)
Number of subjects: 270
Study 27943397 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients exceeding the 6-MMP threshold of 3615 pmol/8 × 108 erythrocytes
Number of subjects: 270
Study 27943397 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 6-MMP concentrations above the threshold
Number of subjects: 270
Study 27943397 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive algorithm based on 6-MMP threshold and risk factors (age, gender, BMI)
Number of subjects: 270
Study 25524249 — intervention group
Group type: EXPERIMENTAL
Intervention: Media Smart
Number of subjects: 1316
Study 25524249 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1316
Study 24089534 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 3862
Study 24089534 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 3862
Study 24089534 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and hs-cTnT
Number of subjects: 3862
Study 21122848 — intervention group
Group type: EXPERIMENTAL
Intervention: 600‐μg oral misoprostol
Number of subjects: 230
Study 21122848 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 230
Study 18817930 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 26
Study 18817930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17530457 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate (100 mg)
Number of subjects: 16
Study 15468399 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative pressure dressing
Number of subjects: 20
Study 15468399 — intervention group
Group type: COMPARATOR
Intervention: Standard bolster dressing
Number of subjects: 20
Study 11854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 500 mg b.i.d. for a mean of 12.5 weeks
Number of subjects: 12
Study 11854606 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 12
Study 10510161 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone (0.5 mg)
Number of subjects: 18
Study 10510161 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with macrogol 4000 (20 g day-1 for 8 days)
Number of subjects: 18
Study 7737960 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam-SR 60 mg/day
Number of subjects: 315
Study 7737960 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam-SR 90 mg/day
Number of subjects: 315
Study 7737960 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam-SR 30 mg/day
Number of subjects: 315
Study 7737960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 1970300 — intervention group
Group type: EXPERIMENTAL
Intervention: bopindolol 1 mg
Number of subjects: 0
Study 1970300 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg
Number of subjects: 0
Study 7359503 — intervention group
Group type: EXPERIMENTAL
Intervention: DES-exposed group
Number of subjects: 429
Study 30853250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (50 mg/kg once daily) at home
Number of subjects: 190
Study 30853250 — intervention group
Group type: COMPARATOR
Intervention: Intravenous flucloxacillin (50 mg/kg every 6 h) in hospital
Number of subjects: 190
Study 25852972 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook-based intervention (FITNET)
Number of subjects: 86
Study 25852972 — intervention group
Group type: COMPARATOR
Intervention: Facebook-based self-help comparison group
Number of subjects: 86
Study 24946799 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (30 sessions)
Number of subjects: 53
Study 24946799 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy (30 sessions)
Number of subjects: 53
Study 24946799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Experimental and Control)
Number of subjects: 53
Study 23002124 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (peginterferon alfa‐2b), 6 μg/kg per week for eight doses, followed by 3 μg/kg per week for up to 252 weeks
Number of subjects: 1256
Study 23002124 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 1256
Study 23002124 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN (peginterferon alfa‐2b)
Number of subjects: 1256
Study 19735181 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g n-3 PUFAs
Number of subjects: 132
Study 19735181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 19735181 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g n-3 PUFAs
Number of subjects: 132
Study 19735181 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g n-3 PUFAs
Number of subjects: 132
Study 17697343 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned vaginal birth after caesarean
Number of subjects: 2314
Study 17697343 — intervention group
Group type: COMPARATOR
Intervention: Planned elective repeat caesarean
Number of subjects: 2314
Study 15260837 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural Disability Awareness and Risk Education (AgDARE) curriculum
Number of subjects: 2000000
Study 15260837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2000000
Study 11432030 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (Copaxone ‐ Teva)
Number of subjects: 0
Study 9007484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus-PRP conjugate vaccine
Number of subjects: 369
Study 9007484 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV components
Number of subjects: 369
Study 9007484 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconjugated PRP
Number of subjects: 369
Study 8393606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(4) p.f.u. dose of rhesus rotavirus serotype 3
Number of subjects: 213
Study 8393606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(5) p.f.u. dose of rhesus rotavirus serotype 3
Number of subjects: 213
Study 8393606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(4) p.f.u. dose of tetravalent rotavirus vaccine
Number of subjects: 213
Study 8393606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(5) p.f.u. dose of tetravalent rotavirus vaccine
Number of subjects: 213
Study 8393606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 8393606 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped vaccines at 10(5) p.f.u. (single serotype and tetravalent)
Number of subjects: 213
Study 3578925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal IgE pentapeptide 0.5%
Number of subjects: 30
Study 3578925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30594314 — intervention group
Group type: EXPERIMENTAL
Intervention: firefighters' worn
Number of subjects: 160
Study 30594314 — intervention group
Group type: EXPERIMENTAL
Intervention: snogg
Number of subjects: 160
Study 30594314 — intervention group
Group type: EXPERIMENTAL
Intervention: flexible tarp
Number of subjects: 160
Study 30594314 — intervention group
Group type: EXPERIMENTAL
Intervention: strap
Number of subjects: 160
Study 30594314 — intervention group
Group type: EXPERIMENTAL
Intervention: inflated stretcher
Number of subjects: 160
Study 27619403 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E supplements (n = 34)
Number of subjects: 68
Study 27619403 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acids and vitamin E co-supplementation
Number of subjects: 68
Study 27619403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 34)
Number of subjects: 68
Study 25739424 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for the prevention of hand eczema
Number of subjects: 19
Study 25739424 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about the recommendations
Number of subjects: 19
Study 25739424 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing products beforehand and collaboration with infection control department
Number of subjects: 19
Study 25739424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit of recommendations with healthcare workers' work
Number of subjects: 19
Study 23511706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 41
Study 23511706 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + LIRET
Number of subjects: 41
Study 23511706 — intervention group
Group type: COMPARATOR
Intervention: LIRET
Number of subjects: 41
Study 21718992 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP (0.030 ethinyl E(2)/0.15 desogestrel) for 12‐16 days
Number of subjects: 228
Study 21718992 — intervention group
Group type: COMPARATOR
Intervention: Long protocol from day 20‐22 of the previous cycle
Number of subjects: 228
Study 19196862 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of low nutrition snacks and beverages from three middle schools
Number of subjects: 6
Study 19196862 — intervention group
Group type: COMPARATOR
Intervention: No systematic changes in three comparison schools
Number of subjects: 6
Study 17264186 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (1 mg/m2.d)
Number of subjects: 20
Study 17264186 — intervention group
Group type: COMPARATOR
Intervention: Non-GH treated control group
Number of subjects: 20
Study 17264186 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 20
Study 14749230 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA-containing food product
Number of subjects: 13
Study 14749230 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate-containing food product
Number of subjects: 13
Study 14749230 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary calcium
Number of subjects: 13
Study 14749230 — intervention group
Group type: COMPARATOR
Intervention: Standard food product with calcium
Number of subjects: 13
Study 11325685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine, 20 mg/kg
Number of subjects: 28
Study 11325685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine, 10 mg/kg
Number of subjects: 28
Study 11325685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine, 40 mg/kg
Number of subjects: 28
Study 11325685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11325685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine
Number of subjects: 28
Study 9621293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment applied at the cannula site after catheter placement and at the end of each dialysis session
Number of subjects: 136
Study 9621293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment
Number of subjects: 136
Study 7772106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery (transcervical resection and laser ablation)
Number of subjects: 204
Study 7772106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic surgery
Number of subjects: 204
Study 7772106 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 204
Study 3310506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1% (Healon)
Number of subjects: 30
Study 3310506 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose 2%
Number of subjects: 30
Study 2363109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (20 mg/ml) with epinephrine (12.5 micrograms/ml)
Number of subjects: 40
Study 2363109 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine (30 mg/ml) with felypressin (0.54 microgram/ml)
Number of subjects: 40
Study 2363109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine (30 mg/ml)
Number of subjects: 40
Study 2363109 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 1244844 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dietary protein content
Number of subjects: 11
Study 1244844 — intervention group
Group type: COMPARATOR
Intervention: Normal dietary protein content
Number of subjects: 11
Study 30893162 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-U prabotulinumtoxinA
Number of subjects: 654
Study 30893162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 28923788 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video game intervention (up to 16 hours over 6 weeks)
Number of subjects: 333
Study 28923788 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video game intervention
Number of subjects: 333
Study 28923788 — intervention group
Group type: COMPARATOR
Intervention: Control video games
Number of subjects: 333
Study 26183690 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (ladder climbing with tail weight, 3 days/week for 12 weeks)
Number of subjects: 2
Study 26183690 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercise program (12 weeks, 1-hour session, 2 days/week)
Number of subjects: 2
Study 26183690 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2
Study 23220355 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu with calorie information and miles to walk to burn those calories
Number of subjects: 802
Study 23220355 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu with calorie information and minutes to walk to burn those calories
Number of subjects: 802
Study 23220355 — intervention group
Group type: EXPERIMENTAL
Intervention: Menu with calorie information
Number of subjects: 802
Study 23220355 — intervention group
Group type: COMPARATOR
Intervention: Menu with no nutritional information
Number of subjects: 802
Study 21508826 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine 20 mg/70 kg/h with rifampicin (600 mg once daily for 5 days)
Number of subjects: 20
Study 21508826 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine 40 mg/70 kg/h with rifampicin (600 mg once daily for 5 days)
Number of subjects: 20
Study 21508826 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine with rifampicin
Number of subjects: 20
Study 19330495 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 301
Study 19330495 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 301
Study 19330495 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 301
Study 16773290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose
Number of subjects: 50
Study 16773290 — intervention group
Group type: COMPARATOR
Intervention: Fibre
Number of subjects: 50
Study 15593207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous cyclophosphamide (IV CYC) regimen (6 pulses of 500 mg given at intervals of 2 weeks) followed by azathioprine (AZA)
Number of subjects: 90
Study 15593207 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly pulses with escalating doses) followed by azathioprine (AZA)
Number of subjects: 90
Study 15593207 — intervention group
Group type: EXPERIMENTAL
Intervention: Early response to therapy (defined as a decrease in serum creatinine level and proteinuria <1 g/24 hours)
Number of subjects: 90
Study 11287243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (brief alcohol abuse prevention program)
Number of subjects: 1000
Study 11287243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1000
Study 9262814 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm arterial occlusion cuffs (AAOC)
Number of subjects: 6
Study 9262814 — intervention group
Group type: COMPARATOR
Intervention: No intervention (without AAOC)
Number of subjects: 6
Study 9262814 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm arterial occlusion cuffs (AAOC) during complex profile
Number of subjects: 6
Study 8333773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent growth hormone treatment (three weeks of every four)
Number of subjects: 0
Study 8333773 — intervention group
Group type: COMPARATOR
Intervention: Continuous growth hormone treatment (daily injection)
Number of subjects: 0
Study 3714912 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 20
Study 3714912 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) infusion
Number of subjects: 20
Study 29701615 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported inattentive ADHD T-scores
Number of subjects: 60
Study 29701615 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hyperactive-impulsive ADHD T-scores
Number of subjects: 60
Study 29701615 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported conduct disorder T-scores
Number of subjects: 60
Study 29701615 — intervention group
Group type: COMPARATOR
Intervention: Parent report measures
Number of subjects: 60
Study 28851412 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured program aimed at improving motor skills
Number of subjects: 368
Study 28851412 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for the first three years)
Number of subjects: 368
Study 26225500 — intervention group
Group type: EXPERIMENTAL
Intervention: QLB with 0.125% bupivacaine 0.2 ml kg⁻¹ (Group 1)
Number of subjects: 50
Study 26225500 — intervention group
Group type: COMPARATOR
Intervention: Control group (QLB with 0.9% Normal saline 0.2 ml kg⁻¹)
Number of subjects: 50
Study 24190233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (EPA 1245 mg/day, DHA 540 mg/day)
Number of subjects: 27
Study 24190233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no EPA or DHA)
Number of subjects: 27
Study 21361734 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone application after showering (standard regimen)
Number of subjects: 10
Study 21361734 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower taken 30 minutes after testosterone application
Number of subjects: 10
Study 21361734 — intervention group
Group type: EXPERIMENTAL
Intervention: Shower taken 15 minutes after testosterone application
Number of subjects: 10
Study 18940887 — intervention group
Group type: EXPERIMENTAL
Intervention: HDB tirofiban
Number of subjects: 692
Study 18940887 — intervention group
Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 692
Study 18940887 — intervention group
Group type: EXPERIMENTAL
Intervention: HDB tirofiban vs abciximab
Number of subjects: 692
Study 18940887 — intervention group
Group type: EXPERIMENTAL
Intervention: HDB tirofiban and abciximab
Number of subjects: 692
Study 18706028 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN, 5 mg/day)
Number of subjects: 5000
Study 18706028 — intervention group
Group type: COMPARATOR
Intervention: No GTN (control)
Number of subjects: 5000
Study 12166558 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training (IT) - work for 30 s at 100% of peak work-rate alternating with 30-s rest intervals, cycling 40 min x day(‐1) and 2 days x week(‐1) for 12 weeks
Number of subjects: 36
Study 12166558 — intervention group
Group type: COMPARATOR
Intervention: Continuous Training (CT) - exercise at 50% of baseline peak work-rate, cycling 40 min x day(‐1) and 2 days x week(‐1) for 12 weeks
Number of subjects: 36
Study 9682028 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP/TAZ)
Number of subjects: 100
Study 9682028 — intervention group
Group type: COMPARATOR
Intervention: Cefepime (CEFP)
Number of subjects: 100
Study 9682028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PIP/TAZ and CEFP
Number of subjects: 100
Study 8576671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCA (Patient-Controlled Analgesia)
Number of subjects: 0
Study 8576671 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (Intramuscular q.i.d. injection and p.r.n. injection)
Number of subjects: 0
Study 2354091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of plain 0.5% bupivacaine injected at L3-4
Number of subjects: 80
Study 2354091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of plain 0.5% bupivacaine injected at L4-5
Number of subjects: 80
Study 509055 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant umbilical vein cytotoxic perfusion with 5-fluorouracil
Number of subjects: 154
Study 509055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no perfusion)
Number of subjects: 154
Study 31340046 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine monitoring for hypoglycemia
Number of subjects: 196
Study 29171020 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on day 1 and 75 mg on day 2)
Number of subjects: 0
Study 29171020 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg on day 1 and 10 mg on day 2)
Number of subjects: 0